| Item type |
文献 / Documents(1) |
| 公開日 |
2020-11-25 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
関連識別子 |
https://doi.org/10.2152/jmi.67.358 |
|
|
関連名称 |
10.2152/jmi.67.358 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Distinct improvement of pulmonary function, ground-glass opacity, hypoxia and physical findings in an idiopathic pulmonary fibrosis patient after pirfenidone treatment : a case report with a review of the literature |
| タイトル別表記 |
|
|
その他のタイトル |
Super-responder to pirfenidone therapy in IPF |
| 著者 |
イマクラ, タケシ
豊田, 優子
佐藤, 正大
小山, 壱也
ニシムラ, ハルカ
香川, 耕造
タカハシ, ナオキ
内藤, 伸仁
ムラカミ, コウジン
河野, 弘
吾妻, 雅彦
篠原, 勉
西岡, 安彦
|
| 抄録 |
|
|
内容記述 |
Background : Pirfenidone (PFD), an anti-fibrosis drug for idiopathic pulmonary fibrosis (IPF), suppresses disease progression and delays decline of forced vital capacity. However, this drug rarely makes marked improvement of pulmonary function, chest high-resolution computed tomography (HRCT) findings and hypoxia. Case presentation : A 59 year-old-man, who was a former smoker and had a history of alcoholic liver cirrhosis, developed exertional dyspnea and was referred to our hospital. HRCT showed honeycomb changes with surrounding ground-glass opacity (GGO) in a predominantly basal and subpleural distribution. He was diagnosed with IPF and the treatment with PFD was started. At 16 months after the start of treatment, the predicted forced vital capacity value markedly improved from 82.9% to 98.6%. His resting-state partial pressure of arterial oxygen while breathing room air increased from a minimum of 54.7 mmHg (at 2 months treatment) to 72.5 mmHg. The GGO observed at diagnosis disappeared in HRCT. But after 32 months of treatment, his general condition got worse gradually, and he died from chronic progression of IPF after 48 months of treatment. Conclusion : Our case suggests that a complication of chronic liver disease and the existence of GGO may be characteristics of super-responder to PFD treatment for IPF patients. |
| キーワード |
|
|
主題 |
idiopathic pulmonary fibrosis |
| キーワード |
|
|
主題 |
pirfenidone |
| キーワード |
|
|
主題 |
chronic liver disease |
| キーワード |
|
|
主題 |
ground-glass opacity |
| キーワード |
|
|
主題 |
super-responder |
| 書誌情報 |
en : The Journal of Medical Investigation
巻 67,
号 3-4,
p. 358-361,
発行日 2020-08
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13496867 |
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13431420 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11166929 |
| 出版者 |
|
|
出版者 |
Tokushima University Faculty of Medicine |
| EID |
|
|
識別子 |
377441 |
| 言語 |
|
|
言語 |
eng |
jmi_67_3-4_358.pdf (614 KB)
